New Trial Results And Updates On Cml, Cll And Mds

New trial results and updates on CML, CLL and MDS

Clinical trial updates in CML

VJHemOnc – Video Journal of Hematology & HemOnc

Updates in CML: recent trials and novel agents

VJHemOnc – Video Journal of Hematology & HemOnc

Management of CMML

Final Thoughts on Clinical Advances in MDS and CML

Final results of the BFORE trial: bosutinib vs imatinib in CP-CML

VJHemOnc – Video Journal of Hematology & HemOnc

FDA Approvals in HNSCC and DLBCL, and Encouraging Data in CLL, MDS, and CMML

Chronic Myelomonocytic Leukemia (CMML): Diagnosis and Therapy

Updates in CLL - 2023 Best of Hematology Conference

Total Health | Oncology

Update on ECOG-ACRIN EA9171: pembrolizumab + TKIs in patients with CML and persistent detectable MRD

VJHemOnc – Video Journal of Hematology & HemOnc

TIDEL-II Trial for CML

Advancements in CML: improving treatment-free remission and novel agents

VJHemOnc – Video Journal of Hematology & HemOnc

Online webinar - Chronic Myeloid Leukaemia (CML) treatment updates

Frontline treatment for CLL: the changing paradigm

VJHemOnc – Video Journal of Hematology & HemOnc

Diagnosis and Therapy of CMML in 2015

Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial

VJHemOnc – Video Journal of Hematology & HemOnc

The genetic complexity of CML beyond BCR-ABL1 & the clinical impact of additional abnormalities

VJHemOnc – Video Journal of Hematology & HemOnc

Latest updates on CML and what this means for you

MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial

VJHemOnc – Video Journal of Hematology & HemOnc

Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

VJHemOnc – Video Journal of Hematology & HemOnc